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ABSTRACT
Processes to attain and maintain the correct three-dimensional shape, known as the 
native conformation, of proteins are vital. However, certain conditions including 
thermal and oxidative stress may cause proteins to partially unfold and aggregate. 
Intracellular and/or extracellular protein aggregates have been identified in a large 
number of diseases, including Alzheimer’s disease, arthritis and type II diabetes. While 
intracellular quality control for the folding state of proteins is well characterized, 
corresponding mechanisms for extracellular protein folding quality control have yet to 
be described.
Clusterin (CLU) is an abundant extracellular chaperone that can stabilize proteins and 
prevent their precipitation during exposure to elevated temperatures or oxidative stress 
in vitro. The work described here demonstrates that CLU stabilizes stressed client 
proteins by forming soluble, high molecular weight (HMW) complexes with them. The 
maximum loading of CLU appears to be at a mass ratio of CLU:stressed client protein 
of approximately 1:2 (irrespective of the identity of the client protein or the temperature 
used to induce heat stress). It was demonstrated that various human plasma proteins 
show increased association with CLU after plasma is subjected to mild shear stress or 
oxidative stress at 37°C - the most abundant of these was fibrinogen (FGN) which  
co-purified with CLU from stressed plasma. In vitro, using purified proteins, heat stress 
of 45°C for 12 h was required to induce FGN precipitation and the formation of HMW 
CLU-FGN complexes. Size exclusion chromatography (SEC) of the stressed plasma 
suggested that a portion of the complexes formed in plasma between CLU and FGN 
may be similar in mass to those formed in vitro.
Using surface plasmon resonance, although CLU was found to bind to megalin, only 
minimal (or no) binding of HMW complexes formed between CLU and glutathione-S-
transferase, citrate synthase or lysozyme was detected. Similarly, negligible binding of 
these complexes to low density lipoprotein receptor superfamily members expressed on 
the surface of the rat yolk sac cell line BN was detected. However, the complexes were 
shown to preferentially bind to the surface of BN cells, peripheral human monocytes 
and rat hepatocytes (more so than uncomplexed CLU or client proteins). In all cases, 
this binding was inhibited by fucoidin (a scavenger receptor inhibitor). Confocal 
microscopy suggested that binding of HMW CLU-stressed protein complexes to the 
v
surface of BN cells or rat hepatocytes was followed by their internalization into 
lysosomes. Furthermore, Western blotting showed that hepatocytes were able to 
degrade the HMW CLU-stressed protein complexes and that the degradation was 
almost completely abolished by inhibiting lysosomal proteases with chloroquine. The 
results of in vivo biodistribution studies in Sprague Dawley rats were highly consistent 
for several different HMW CLU-stressed protein complexes. Intravenous 123I-labelled
HMW CLU-stressed protein complexes were cleared more efficiently from circulation 
compared to free CLU and the uncomplexed client proteins. The liver and to a lesser 
degree the spleen appeared to be the key organs responsible for the uptake of 
complexes and this uptake was inhibited by pre-injection of the animals with fucoidin. 
The findings of this study suggest an important role for CLU in global quality control of 
extracellular protein folding. It appears likely that stressed (partially unfolded) 
extracellular proteins are stabilized and held in solution by CLU and that CLU-stressed 
protein complexes are subsequently taken up by fucoidin-inhibitable cell surface 
receptors for subsequent degradation within lysosomes. The precise physical 
characteristic or binding site that targets CLU-stressed protein complexes for receptor-
mediated uptake remains to be identified and further work is needed to determine the 
particular receptor(s) involved. The findings of this study support a model in which 
complexation with CLU is an important first step in the targeted disposal of stressed 
proteins via scavenger-like endocytic receptors.
vi
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